Insider · CIK 0001842190
Elizabeth Yeu Lin
Files at STAA (STAAR SURGICAL CO), TARS (Tarsus Pharmaceuticals, Inc.). First filing Jun 17, 2025, latest Sep 9, 2026.
Elizabeth Yeu Lin files SEC Form 4 as officer and director at TARS (Tarsus Pharmaceuticals, Inc.), and also at STAA (STAAR SURGICAL CO). Since Jun 17, 2025, Elizabeth Yeu Lin has reported 0 open-market buys worth $0 and 5 open-market sells worth $2.4M, the latest filed on Sep 9, 2026.
A track record needs three past buys with six months of prices behind them; Elizabeth Yeu Lin has 0, so none is measured yet.
The newest scored trade: sold $1.2M of TARS on Sep 4, 2026, filed Sep 9, 2026, scored 55 (moderate), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 4 sells worth $2.4M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
TARS: Tarsus Pharmaceuticals, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 55Moderate | Tarsus Pharmaceuticals, Inc. | $1.2M 13,953 shares | -105% | - | |
| 44Moderate | Tarsus Pharmaceuticals, Inc. | $898k 11,578 shares | -50% | - | |
| 39Weak | Tarsus Pharmaceuticals, Inc. | $78k 1,144 shares | -5% | +80% from low-15% from high | |
| 26Weak | Tarsus Pharmaceuticals, Inc. | $165k 2,078 shares | -9% | +102% from low-5% from high | |
| 26Weak | Tarsus Pharmaceuticals, Inc. | $41k 1,006 shares | -12% | +33% from low-27% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 16, 2025 | TARS Tarsus Pharmaceuticals, Inc. | 1,006 0.00% of outstanding | $41k | Jun 16, 2025 | none |
Transactions
Every row this insider has filed, 24 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 4, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -5,387 | $85.00 | $458k | 7,933 | 34 d ago |
| Sep 4, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -5,386 | $90.00 | $485k | 2,547 | 34 d ago |
| Sep 4, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stockindirect: By Spouse's Roth IRA10b5-1 | -1,590 | $85.00 | $135k | 3,180 | 34 d ago |
| Sep 4, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stockindirect: By Spouse's Roth IRA10b5-1 | -1,590 | $90.00 | $143k | 1,590 | 34 d ago |
| Sep 1, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -4,601 | $73.86 | $340k | 18,707 | 40 d ago |
| Sep 2, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -5,387 | $80.00 | $431k | 13,320 | 40 d ago |
| Sep 2, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stockindirect: By Spouse's Roth IRA10b5-1 | -1,590 | $80.00 | $127k | 4,770 | 40 d ago |
| Mar 17, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -375 | $69.42 | $26k | 24,077 | Mar 19, 2026 |
| Mar 18, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -379 | $68.71 | $26k | 23,698 | Mar 19, 2026 |
| Mar 19, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -390 | $67.00 | $26k | 23,308 | Mar 19, 2026 |
| Mar 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Common Stock | +2,511 | - | - | 24,452 | Mar 17, 2026 |
| Mar 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -2,511 | $0.00 | $0 | 7,534 | Mar 17, 2026 |
| Mar 5, 2026 | TARS Tarsus Pharmaceuticals, Inc. | AGrant or award Stock Option (right to buy)derivative | +27,310 | $0.00 | $0 | 27,310 | Mar 9, 2026 |
| Mar 5, 2026 | TARS Tarsus Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +17,161 | $0.00 | $0 | 17,161 | Mar 9, 2026 |
| Dec 15, 2025 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Common Stock | +6,819 | - | - | 24,019 | Dec 17, 2025 |
| Dec 16, 2025 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,078 | $79.50 | $165k | 21,941 | Dec 17, 2025 |
| Dec 15, 2025 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -6,819 | $0.00 | $0 | 20,459 | Dec 17, 2025 |
| Jun 18, 2025 | STAA STAAR SURGICAL CO | AGrant or award Restricted Stock Unitsderivative | +5,341 | $0.00 | $0 | 5,341 | Jun 20, 2025 |
| Jun 18, 2025 | STAA STAAR SURGICAL CO | AGrant or award Common Stock Optionsderivative | +9,708 | $0.00 | $0 | 9,708 | Jun 20, 2025 |
| Jun 13, 2025 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Common Stock | +3,350 | - | - | 8,700 | Jun 17, 2025 |
| Jun 16, 2025 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -1,006 | $41.08 | $41k | 7,694 | Jun 17, 2025 |
| Jun 13, 2025 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -3,350 | $0.00 | $0 | 0 | Jun 17, 2025 |
| Nov 4, 2024 | TARS Tarsus Pharmaceuticals, Inc. | AGrant or award Stock Option (right to buy)derivative | +41,074 | $0.00 | $0 | 41,074 | Nov 6, 2024 |
| Nov 4, 2024 | TARS Tarsus Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +27,278 | $0.00 | $0 | 27,278 | Nov 6, 2024 |
Questions about Elizabeth Yeu Lin
Answered from the filings on this page, as of the latest one.
Is Elizabeth Yeu Lin buying or selling?
In the last 12 months Elizabeth Yeu Lin reported 0 open-market buys worth $0 and 4 open-market sells worth $2.4M on SEC Form 4; the latest was sold $1.2M of TARS on Sep 4, 2026. Grants, option exercises and tax withholding are not counted.
How did Elizabeth Yeu Lin's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Elizabeth Yeu Lin has 0.
Where does Elizabeth Yeu Lin file Form 4?
Elizabeth Yeu Lin has filed Form 4 at TARS (Tarsus Pharmaceuticals, Inc.) as Chief Medical Officer; STAA (STAAR SURGICAL CO). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.